摘要
胰腺癌症是最难诊断和治疗的恶性肿瘤之一,其特点是发病隐匿、进展迅速、预后差。目前,手术治疗仍然是首选治疗方法。然而由于缺乏早期症状,大约70%的患者在确诊时已经出现局部扩散或远端转移,从而无法进行手术治疗。由此看来,早期检测是提高患者治疗效果和预后的有效途径。临床上使用的成像方法(CT、MRI、EUS等)通常无法检测早期病变,并且很容易受到操作员的影响。常规临床标志物如CA19-9、CA125、CA242和CEA受到限制,其敏感性或特异性不令人满意。因此,寻找新的具有高敏感性和特异性的标志物是实现胰腺癌早期检测的关键。近年来,对生物标志物的广泛研究主要集中在遗传学、转录组学和蛋白质组学上。特别是由microRNA(miRNA)、long non-coding RNA(lncRNA)和circRNA(circRNA)组成的非蛋白质编码RNA(non-protein coding RNA,ncRNA)为胰腺癌的早期检测提出了许多新思路。然而,其中绝大多数仍处于实验室研究阶段。而一项成熟的生物标志物研究应该整合基因组学、转录组学、蛋白质组学或代谢组学的数据,并结合患者的个体特征(如体重指数、糖尿病史、吸烟、饮酒和其他危险因素)进行大规模、前瞻性和验证性研究。
Pancreatic cancer is one of the most difficult malignant tumors to be diagnosed and treated,with insidious onset,rapid progression and poor prognosis.Presently,surgery is still the preferred method for the treatment of pancreatic cancer.However,due to lack of early symptoms,approximately 70%of patients are diagnosed with local spread or distant metastasis,making it impossible to undergo surgical treatment.Development of effective approaches for better administration of the disease will be unmet and effective way for reducing the mortality and the morbidity.Unfortunately,detection of pancreatic cancer,especially at early stage,is challenged by the lack of highly sensitive and specific biomarkers.Imaging methods(CT,MRI,EUS,etc.)often fail to detect early lesions and is easily influenced by operator.Routine clinical markers such as CA19-9,CA125,CA242 and CEA were limited with unsatisfactory sensitivity or specificity.In recent years,extensive studies on biomarkers mainly focused on genetics,transcriptomics,and proteomics.Especially,non-protein coding RNA(ncRNA)consisting of microRNA(miRNA),long non-coding RNA(lncRNA)and circular RNA(circRNA)have proposed many new ideas about early detection of pancreatic cancer.However,the majority of them remain in the laboratory research stage.Few of them,to our knowledge,have gone into clinical practice.A mature study on biomarker may integrate data from genomics,transcriptomics,proteomics,or metabolomics,and combine with individual characteristics of patients(such as body mass index,history of diabetes,smoking,drinking and other risk factors)through largescale,prospective and validation studies.
作者
龚姣姣
黄晶
肖桂山
GONG Jiao-Jiao;HUANG Jing;XIAO Gary G(Kante Biotechnologies,Inc,Shenzhen 518000,China;School of Chemical Engineering,Dalian University of Technology,Dalian 116024,China;College of Chemical and Environmental Engineering,Shenzhen University,Shenzhen 518061,China;Center for Functional Genomics and Proteomics,Creighton University Medical Center,Omaha,NE 68178,USA)
出处
《生物化学与生物物理进展》
SCIE
CAS
CSCD
北大核心
2023年第5期1069-1076,共8页
Progress In Biochemistry and Biophysics
基金
国家自然科学基金(81770846,81803024)
胰腺癌研究Hirshberg基金(GX20171003858,GX20191005878)
大连理工大学基础研究经费(DUT17ZD308)
康德种子基金(KD2020092201)资助项目。
